Related references
Note: Only part of the references are listed.Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma
Jeffrey A. Jones et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies
Elias Jabbour et al.
HAEMATOLOGICA (2014)
Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas
Jonathan W. Friedberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Pharmacological and genomic profiling identifies NF-kappa B-targeted treatment strategies for mantle cell lymphoma
Rami Rahal et al.
NATURE MEDICINE (2014)
The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: Insight into disease biology and new targeted therapies
Jan A. Burger et al.
SEMINARS IN CANCER BIOLOGY (2014)
Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management
Julie M. Vose
AMERICAN JOURNAL OF HEMATOLOGY (2013)
P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse
Sunil Iyengar et al.
BLOOD (2013)
Differences in gene expression and cytokine levels between newly diagnosed and chronic pediatric ITP
Margareta Jernas et al.
BLOOD (2013)
A myeloproliferative neoplasm with translocation t(8;9)(p22;p24) involving JAK2 gene
Nakhle Saba et al.
BLOOD (2013)
SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma
Maria Carmela Vegliante et al.
BLOOD (2013)
The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma
Barbara Meissner et al.
BLOOD (2013)
Using primary site as a predictor of survival in mantle cell lymphoma
Alexander J. Ambinder et al.
CANCER (2013)
ABT-199: Taking Dead Aim at BCL-2
Matthew S. Davids et al.
CANCER CELL (2013)
Open questions in the management of mantle cell lymphoma
Zhi-Ming Li et al.
CANCER TREATMENT REVIEWS (2013)
Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1
David Chiron et al.
CELL CYCLE (2013)
Sorafenib Inhibits Cell Migration and Stroma-Mediated Bortezomib Resistance by Interfering B-cell Receptor Signaling and Protein Translation in Mantle Cell Lymphoma
Silvia Xargay-Torrent et al.
CLINICAL CANCER RESEARCH (2013)
Recent advances in the management of mantle cell lymphoma
Noridza Rivera-Rodriguez et al.
CURRENT OPINION IN ONCOLOGY (2013)
Biology of Chronic Lymphocytic Leukemia in Different Microenvironments Clinical and Therapeutic Implications
Yair Herishanu et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2013)
Targeting B-Cell Receptor Signaling for Anticancer Therapy: The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Induces Impressive Responses in B-Cell Malignancies
Adrian Wiestner
JOURNAL OF CLINICAL ONCOLOGY (2013)
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
Ranjana H. Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis
Munevver Cinar et al.
LEUKEMIA RESEARCH (2013)
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers et al.
NATURE MEDICINE (2013)
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Landscape of somatic mutations and clonal evolution in mantle cell lymphoma
Silvia Bea et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
B-cell receptor signaling as a driver of lymphoma development and evolution
Carsten U. Niemann et al.
SEMINARS IN CANCER BIOLOGY (2013)
Next-Generation Sequencing in Chronic Lymphocytic Leukemia
Neus Villamor et al.
SEMINARS IN HEMATOLOGY (2013)
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
John P. Leonard et al.
BLOOD (2012)
Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma
Lina Nygren et al.
BLOOD (2012)
Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia
Matthew S. Davids et al.
BLOOD (2012)
Molecular Subsets of Mantle Cell Lymphoma Defined by the IGHV Mutational Status and SOX11 Expression Have Distinct Biologic and Clinical Features
Alba Navarro et al.
CANCER RESEARCH (2012)
TRIP12 and UBR5 Suppress Spreading of Chromatin Ubiquitylation at Damaged Chromosomes
Thorkell Gudjonsson et al.
CELL (2012)
Aurora A Inhibitor (MLN8237) plus Vincristine plus Rituximab Is Synthetic Lethal and a Potential Curative Therapy in Aggressive B-cell Non-Hodgkin Lymphoma
Daruka Mahadevan et al.
CLINICAL CANCER RESEARCH (2012)
Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53
Chris T. Williamson et al.
EMBO MOLECULAR MEDICINE (2012)
The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index
Julia Slotta-Huspenina et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma
Christoph Renner et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Molecular pathogenesis of mantle cell lymphoma
Pedro Jares et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
Andrew W. Roberts et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia
Yair Herishanu et al.
BLOOD (2011)
Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era
Patricia Perez-Galan et al.
BLOOD (2011)
Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation
Patricia Perez-Galan et al.
BLOOD (2011)
Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases
Anastasia Hadzidimitriou et al.
BLOOD (2011)
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
Sarah E. M. Herman et al.
BLOOD (2011)
Mantle Cell Lymphoma International Prognostic Index but Not Pretransplantation Induction Regimen Predicts Survival for Patients With Mantle-Cell Lymphoma Receiving High-Dose Therapy and Autologous Stem-Cell Transplantation
Lihua E. Budde et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
Jonathan W. Friedberg et al.
BLOOD (2010)
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
Wyndham H. Wilson et al.
LANCET ONCOLOGY (2010)
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
R. Eric Davis et al.
NATURE (2010)
Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Georg Hess et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2
M. Klier et al.
LEUKEMIA (2008)
Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival
Adrian Wiestner et al.
BLOOD (2007)
The concept of synthetic lethality in the context of anticancer therapy
WG Kaelin
NATURE REVIEWS CANCER (2005)
Variations in ATM protein expression during normal lymphoid differentiation and among B-cell-derived neoplasias
J Starczynski et al.
AMERICAN JOURNAL OF PATHOLOGY (2003)
Share Paper
